In Nexium Case, FDA Pre-Emption Wins; 3rd Circuit Rules For AstraZeneca
This article was originally published in The Tan Sheet
Executive Summary
An appellate court threw out a false advertising suit against AstraZeneca, concluding that since the company's ads complied with FDA-approved labeling, they were not subject to state consumer fraud laws
You may also be interested in...
Federal Pre-emption Defense Under Fire In Draft House Bills
A one-sentence provision tucked into draft House legislation renewing FDA's drug user fee program seeks to weaken manufacturers' ability to use FDA approval as a defense in state product liability lawsuits
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands